Calosyn Pharma Inc

At Calosyn Pharma, we are pioneering a new era in osteoarthritis (OA) treatment. Our lead candidate, CAL-05CR, is a non-steroid sustained-release injection designed to not only provide immediate and long-lasting pain relief but also to address the underlying pathophysiology of OA. With a mechanism that targets both symptoms and disease progression, CAL-05CR has the potential to disrupt the ten billion dollar OA market and offer a meaningful solution for the millions of patients. A team of seasoned experts in orthopaedic surgery, drug delivery, and clinical development backs Calosyn. Calosyn is leveraging a capital-efficient pathway to accelerate development and bring this innovative therapy to patients. We have successfully demonstrated calcium channel blockers as a treatment option in Phase 1 studies and other clinical trials. Our active ingredient has shown significant pain reduction and has a favourable safety profile. We are now raising seven million dollars to open the IND and manufacture the therapeutic at scale for a Phase 2 study. Join us on our mission to transform the standard of care for osteoarthritis.